Vertex has just filed for approval of Kalydeco for CF patients aged 18 and older who have the R117H mutation, the most common residual function mutation, which could add another 300 patients to ...

Yesterday the expert panel voted 13 to two in favour of extending the indications of Kalydeco (ivacaftor) to include patients aged six and older with a mutation in the R117H gene, who number ...